AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Palvella Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0055C3N66
125.10▼ 1.29 (-1.02%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
126.39
Day's Range
121.34 – 125.93
52-Week Range
68.96 – 161.38
Volume
161.8K
Avg Volume
226.9K
Share Statistics
Shares Outstanding
Employees
29
Exchange
XNAS
Listed
2024-12-16
Share count as of July 31, 2026

Palvella Therapeutics, Inc. Common Stock (PVLA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Palvella Therapeutics, Inc. Common Stock (PVLA)
What is Palvella Therapeutics, Inc. Common Stock's Market Cap?
Palvella Therapeutics, Inc. Common Stock's Market Cap is $1.8B, based on as-reported figures from SEC (XBRL) filings.
What is Palvella Therapeutics, Inc. Common Stock's Enterprise Value?
Palvella Therapeutics, Inc. Common Stock's Enterprise Value is $1.6B, based on as-reported figures from SEC (XBRL) filings.
What is Palvella Therapeutics, Inc. Common Stock's Net Income (TTM)?
Palvella Therapeutics, Inc. Common Stock's Net Income (TTM) is -$61.7M, based on as-reported figures from SEC (XBRL) filings.
What is Palvella Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Palvella Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -4.28, based on as-reported figures from SEC (XBRL) filings.
What is Palvella Therapeutics, Inc. Common Stock's Net Debt?
Palvella Therapeutics, Inc. Common Stock's Net Debt is -$250.6M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · PVLAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses
Research and development
General and administrative
Total operating expenses
Operating loss
Other (expense) income:
Interest expense - royalty agreement
Fair value adjustments on derivative liabilities - royalty agreement
Fair value adjustments on derivative liabilities - contingent value right liability——
Interest income, net
Other (expense) income, net
Loss before income taxes
Income tax benefit (expense)
Net loss
Net loss per share of Common Stock - basic (in dollars per share)
Net loss per share of Common Stock - diluted (in dollars per share)